Английская Википедия:Amibegron
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Drugbox
Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.[1][2]
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3]
References
Шаблон:Antidepressants Шаблон:Anxiolytics Шаблон:Adrenergics
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.